BioPharma Resources

Drug Trial Radar · NCT06208488

A Study of Subcutaneous Gefurulimab Using Prefilled Syringe Versus Autoinjector in Healthy Adult Participants

A Phase 1, Open-label, Randomized, Parallel-group Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, Immunogenicity, and Device Performance of ALXN1720 (Gefurulimab) Administered Subcutaneously Using Prefilled Syringe Versus Autoinjector in Adult Healthy Participants

Last checked: Nov 19, 2026Latest source record: Oct 23, 2024 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingRandomized with 175 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

175

Actual

Start

Nov 22, 2023

Primary completion

Sep 17, 2024

Study completion Sep 28, 2024

Sponsor

Lead sponsor
Alexion Pharmaceuticals, Inc.AstraZeneca (AZN)
Sponsor type
Industry
Collaborators
Parexel
First posted
Jan 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1
Allocation
Randomized
Model
Parallel
Masking
Single (outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 18 years, up to 65 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

This study will evaluate the pharmacokinetics (PK), pharmacodynamics (PD), safety, immunogenicity, and device performance of gefurulimab.

Conditions

  • Healthy Adult Participants

Interventions

  • Gefurulimab PFS-SDDrug

    Participants will receive a single 600 mg dose of Gefurulimab PFS-SD subcutaneously (SC) on Day 1.

  • Gefurulimab AIDrug

    Participants will receive a single 600 mg dose of Gefurulimab AI subcutaneously (SC) on Day 1.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Area under the serum concentration-time curve from time zero to the last measurable concentration (AUClast)Time frame: Day 1 up to early discontinuation or Day 92
  2. Area under the serum concentration-time curve from time zero to time infinity (AUCinf)Time frame: Day 1 up to early discontinuation or Day 92
  3. Maximum (peak) concentration observed after study intervention administration (Cmax)Time frame: Day 1 up to early discontinuation or Day 92

Locations

2 sites in 1 country. Site status is shown where the registry gives one.

  • Research Site

    Toronto, Ontario, Canada

  • Research Site

    Laval, Quebec, Canada

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.